Clinical Trials
6 trialsNCT00087451 2015-08-19
Safety Study of AP23573 in Patients With Progressive or Recurrent Glioma (8669-023)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00288431 2015-07-22
Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01010672 2015-04-30
Phase II Study of Ridaforolimus (MK-8669) With Metastatic Bone or Soft-tissue Sarcoma Patients (MK-8669-030 AM1)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00093080 2015-02-13
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00538239 2015-02-13
SUCCEED
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01296659 2012-07-12
Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Soft Tissue Sarcoma
The University of Texas Health Science Center at San Antonio
Phase 1 Withdrawn